Publications

Peer-Reviewed Publications

• Andraka-Christou B, McAvoy E^s, Ohama M, Smart R, Vaiana M, Taylor E, Stein BD. Systematic identification and categorization of opioid prescribing/dispensing policies in 16 states & Washington D.C. [published online ahead of print]. Pain Medicine. 2022; pnac124. doi:10.1093/pm/pnac124 (Impact factor 3.7; 2^nd Quartile in Medicine, General & Internal). Available at https://academic.oup.com/painmedicine/advance-article/doi/10.1093/pm/pnac124/6671855.
• Andraka-Christou B, Totaram R, Nguyen TD. Comprehensive analysis of discharge reasons from methadone outpatient treatment programs [published online ahead of print]. Am J on Addictions. 2022. doi:10.1111/ajad.13326 (Impact factor 3.6; 3^rd Quartile in Substance Abuse). Available at: https://onlinelibrary.wiley.com/doi/10.1111/ajad.13326
• Andraka-Christou B, Page C, Schoebel V, Buche J, Haffajee RL. Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants. Addict Sci Clin Pract. 2022;17(43). doi: 10.1186/s13722-022-00321-6 (Impact factor 4.7; 2^nd Quartile in Substance Abuse). Available at: https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-022-00321-6
• Ahmed F, Andraka-Christou B, Clark MH, Totaram R, Atkins DN, del Pozo. Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost. Health Justice. 2022;10(24). doi:10.1186/s40352-022-00188-4 (Impact factor 3.22; 1^st Quartile in Law). Available at: https://pubmed.ncbi.nlm.nih.gov/35895179/
• Nguyen TD, Chua KP, Andraka-Christou B, Bradford D, Simon K. Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021. JAMA Health Forum. 2022;3(7):e221821. doi:10.1001/jamahealthforum.2022.1821 (Impact factor and quartile not yet available for this new journal). Available at: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2794135
• Andraka-Christou B, Saloner B, Gordon AJ, Totaram R^s, Randall-Kosich O^s, Golan M, , Stein BD. Laws for expanding access to medications for opioid use disorder: A legal analysis of 16 states & Washington D.C. [published online ahead of print, 2022 Jun 30].  Am J Drug Alcohol Abuse. 2022;1-12. doi:10.1080/00952990.2022.2082301 (Impact Factor 3.67; Quartile 2 in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/35772010/
• Ray B, Kunkel T, Bryant K, Hedden B, Andraka-Christou B, O’Neil M, Huynh P. Client attitudes toward virtual treatment court [published online ahead of print, 2022 Jun 28]. J Subst Abuse Treat. 2022;140:108833. doi:10.1016/j.jsat.2022.108833 (impact factor 4.0; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/35779292/
• Andraka-Christou B, Randall-Kosich O^s, Golan M, Totaram R^s, Saloner B, Gordon AJ, Stein BD. A national survey of state laws regarding medications for opioid use disorder in problem-solving courts. Health Justice. 2022;10(1):14. Published 2022 Mar 31. doi:10.1186/s40352-022-00178-6. (Impact factor 3.22; 1^st Quartile in Law). Available at: https://pubmed.ncbi.nlm.nih.gov/35357599/
• Andraka-Christou B, Nguyen T, Harris S, Atkins DN, Totaram R, Golan O, Koval A, Madeira J. Harm reduction policy support among students at two US universities. Subst Use Misuse. 2022;57(8):1185-1195. doi:10.1080/10826084.2022.2069265 (impact factor 2.17; 3^rd Quartile in Psychology). Available at: https://pubmed.ncbi.nlm.nih.gov/35491710/
• Golan O^s, Totaram R^s, Perry E, Fortson K, Rivera-Atilano R^s, Entress R^s, Andraka-Christou B, Whitaker D, Pigott T. Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder. Drug Alcohol Depend. 2022;235:109445. doi:10.1016/j.drugalcdep.2022.109445 (impact factor 5.0; 1^st Quartile in Psychiatry). Available at: https://pubmed.ncbi.nlm.nih.gov/35430522/
• Harrison JM, Kerber R, Andraka-Christou B, Sorbero M, Stein BD. State policies and buprenorphine prescribing by nurse practitioners and physician assistants [published online ahead of print, 2022 Apr 18]. Med Care Res Rev. 2022;10775587221086489. doi:10.1177/10775587221086489 (impact factor 3.6; 1st Quartile in Health Policy & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/35435071/
• Andraka-Christou B, Gordon AJ, Spetz J, Totaram R^s, Golan M^s, Randall-Kosich O^s, Harrison JM, Calder S, Kertesz S, Stein BD. Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing. J Subst Abuse Treat. 2022;138:108715. doi:10.1016/j.jsat.2021.108715 (impact factor 4.0; 2^nd Quartile in Substance Abuse). Available at:  https://pubmed.ncbi.nlm.nih.gov/35067400/
• Nguyen T, Andraka-Christou B, Bradford D, Simon K. Opting into the Public List of Data-Waivered Practitioners: Variations by Specialty, Treatment Capacity, and Practitioner Characteristics. J Addict Med. 2022;16(3):e197-e202. doi:10.1097/ADM.0000000000000911 (flagship journal of the American Society of Addiction Medicine; impact factor 3.93; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34669615/
• Andraka-Christou B, Totaram R^s, Randall-Kosich O^s. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses. Subst Abus. 2022;43(1):415-424. doi:10.1080/08897077.2021.1944957 (impact factor 3.85; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34214400/
• Andraka-Christou B, Clark MH, Atkins DN, del Pozo B. Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder. Subst Abuse. 2021;43(1):425-432.  doi: 10.1080/08897077.2021.1944958 (impact factor 3.85; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34236297/
• Andraka-Christou B. Addressing racial & ethnic disparities in utilization of medications for opioid use disorder. Health Aff (Millwood). 2021;40(6):920-927. doi:10.1377/hlthaff.2020.02261 (Impact Factor 7.03; 1^st Quartile in Health Policy & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/34097509/
• Nguyen T, Cantor, J, Andraka-Christou B, Bradford W, Simon K. Where did the behavioral health workforce grow between 2011 and 2019? Evidence from census data. J Subst Abuse Treat. 2021;130:108482. doi: 10.1016/j.jsat.2021.108482. (impact factor 4.0; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34118714/
• Cantor J, Kravitz D, Sorbero M, Andraka-Christou B, Whaley C, Bouskill K, Stein B. Trends in visits to substance use disorder treatment facilities in 2019. J Subst Abuse Treat. 2021;130:108482. doi:10.1016/j.jsat.2021.108482 (impact factor 4.0; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34118714/
• Andraka-Christou B, Gordon A, Bouskill K, Smart R, Randall-Kosich O^s, Golan M^s, Totaram R^s, Stein B. Toward a typology of office-based buprenorphine treatment laws: Themes from a review of state laws. J Addict Med. 2022;16(2):192-207. doi:10.1097/ADM.0000000000000863 (flagship journal of the American Society of Addiction Medicine; impact factor 3.93; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34014209/
• Andraka-Christou B, Bouskill K, Haffajee R, Randall-Kosich O^s, Golan M^s, Totaram R^s, Gordon A, Stein B. Common themes in early state responses to substance use disorder treatment during COVID-19. Am J Drug Alcohol Abuse. 2021;47(4):486-496. doi:10.1080/00952990.2021.1903023 (Impact Factor 3.67; Quartile 2 in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/33909518/
• Nguyen T, Muench U, Andraka-Christou B, Simon K, Bradford WD, Spetz J. The Association between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine after the 2016 Opioid Bill. Med Care Res Rev. 2022;79(2):290-298. doi:10.1177/10775587211004311 (impact factor 3.6; 1^st Quartile in Health Policy & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/33792414/
• Saloner B, Andraka-Christou B, Gordon A, Stein B. It will end in tiers: A strategy to include “dabblers” in the buprenorphine workforce after the X-waiver. Subst Abuse. 2020;42(2):153-157. doi:10.1080/08897077.2021.1903659. (impact factor 3.85; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/33798034/
• Andraka-Christou B, Nguyen T, Harris S, Madeira J, Totaram R ^S, Randall-Kosich O ^S, Atkins D. A pilot study of U.S. college students’ 12-step orientation and the relationship with medications for opioid use disorder [published online ahead of print, 2021 Feb 12]. J Am Coll Health. 2021;1-9. doi:10.1080/07448481.2020.1865376 (impact factor 3.56; 2^nd Quartile in Public Health, Environmental Health & Occupational Health). Available at: https://pubmed.ncbi.nlm.nih.gov/33577404/
• Andraka-Christou B, Randall-Kosich O ^S, Totaram R ^S. Designing an “ideal” substance use disorder treatment center: Perspectives of people who have utilized medications for opioid use disorder. Qual Health Res. 2021;31(3):512-522. doi:10.1177/1049732320971231 (impact factor 5.04; 1^st Quartile in Social Sciences & Biomedical). Available at: https://pubmed.ncbi.nlm.nih.gov/33213261/
• Andraka-Christou B, Atkins D. Whose opinion matters about medications for opioid use disorder? A Cross-sectional survey of social norms among court staff. Subst Abus. 2021;42(4):735-750. doi:10.1080/08897077.2020.1846666 (impact factor 3.85; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/33284059/
• Andraka-Christou B, Atkins D. Beliefs about Medications for Opioid Use Disorder among Florida Criminal Problem-Solving Court & Dependency Court Staff. Am J Drug Alcohol Abuse. 2020;46(6):749-760. doi:10.1080/00952990.2020.1807559 (Impact Factor 3.67; Quartile 2 in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/32969757/
• Haffajee R, Andraka-Christou B, Attermann J, Cupito A, Buche J, Beck A. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prev Policy. 2020;15(1):69. Published 2020 Sep 14. doi:10.1186/s13011-020-00312-3 (impact factor 3.12; H index 40; 3rd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/32928272/
• Mazurenko O, Andraka-Christou, B, Bair M, Kara A, Harle C. Clinical perspectives on hospitals’ role in the opioid epidemic. BMC Health Serv Res. 2020;20(1):521. Published 2020 Jun 8. doi:10.1186/s12913-020-05390-4 (impact factor 3.3; 3^rd Quartile in Health Care Sciences & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/32513158/
• Andraka-Christou B, Atkins D, Madeira J, Silverman R. Receipt of Training about Medication for Opioid Use Disorder from Pharmaceutical Manufacturers: A Preliminary Study of Florida Criminal Problem-Solving and Dependency Court Staff. Drug Alcohol Rev. 2020;39(5):583-587. doi:10.1111/dar.13090 (impact factor 3.3; 3^rd Quartile in Health Care Sciences & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/32394525/
• Andraka-Christou B, Nguyen T, Harris S, Madeira J, Randall-Kosich O^s, Totaram R^s, Atkins D, Ford J. College students’ perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities. Am J Drug Alcohol Abuse. 2020;46(5):589-603. doi:10.1080/00952990.2020.1757686 (Impact Factor 3.67; Quartile 2 in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/32543922/
• Andraka-Christou B, Nguyen T, Bradford D, Simon K. Assessing the Impact of Drug Courts on Provider-Directed Marketing Efforts by Manufactures of Medications for the Treatment of Opioid Use Disorder. J Subst Abuse Treat. 2020;110:49-58. doi:10.1016/j.jsat.2019.12.004 (impact factor 4.0; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/31952628/
• Nguyen T, Andraka-Christou B, Simon K, Bradford D. Comparison of rural versus urban direct-to-physician commercial promotion of medications for treating opioid use disorder. JAMA Netw Open. 2019;2(12):e1916520. Published 2019 Dec 2. doi:10.1001/jamanetworkopen.2019.16520 (impact factor 8.5; 1st Quartile in Medicine – General & Internal). Available at: https://pubmed.ncbi.nlm.nih.gov/31790568/
• Dilulio J, Militello L, Andraka-Christou B, Cook R, Hurley R, Downs S, Anders S, Mamlin B, Danielson E^s, Harle C. Factors that influence changes to existing chronic pain management plans. J Am Board Fam Med. 2020;33(1):42-50. doi:10.3122/jabfm.2020.01.190284 (impact factor 3.01; 2^nd Quartile in Medicine – General & Internal). Available at: https://pubmed.ncbi.nlm.nih.gov/31907245/
• Staton M, Andraka-Christou B, Watson D. Isomorphic pressures on jail diversion: From serious mental illness to opioid use disorder. The Prison Journal. 2021;101(2):187-209. doi:10.1177/0032885521991092 (impact factor 1.63; 4^th Quartile in Criminology). Available at: https://journals.sagepub.com/doi/abs/10.1177/0032885521991092
• Danielson E, Mazurenko O, Andraka-Christou B, Dilulio J, Downs S, Hurley R, Harle C. An analysis of primary care clinician communication about risk, benefits, and goals, related to opioid therapy. MDM Policy Pract. 2019;4(2):2381468319892572. Published 2019 Dec 10. doi:10.1177/2381468319892572 (impact factor 3.6; 2^nd Quartile in Health Policy & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/31853506/
• Randall-Kosich O^s, Andraka-Christou B, Totaram R^s, Alamo J^s, Nadig M^s. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment among a Sample of White Individuals with Opioid Use Disorder. J Addict Med. 2020;14(4):e44-e52. doi:10.1097/ADM.0000000000000584 (flagship journal of the American Society of Addiction Medicine; impact factor 3.93; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/31651562/  
• Andraka-Christou B, Gabriel M, Madeira J, Silverman R. Court personnel attitudes towards medications for opioid use disorder: a state-wide survey. J Subst Abuse Treat. 2019;104:72-82. doi:10.1016/j.jsat.2019.06.011 (impact factor 4.0; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/31370988/
• Nguyen T, Andraka-Christou B, Bradford W, Kosali S. Provider-Directed Marketing May Increase Prescribing of Medications for Opioid Use Disorder. J Subst Abuse Treat. 2019;104:104-115. doi:10.1016/j.jsat.2019.06.014 (impact factor 4.0; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/31370974/
• Andraka-Christou B, Alex B^s, Madeira J. College student preferences regarding educational videos and substance use disorder content, format, and style. Subst Use Misuse. 2019;54(8):1400-1407. doi:10.1080/10826084.2019.1581816 (impact factor 2.17; 3^rd Quartile in Psychology). Available at: https://pubmed.ncbi.nlm.nih.gov/30860935/
• Mazurenko O, Andraka-Christou B, Bair M, Kara A, Harle C. A. Balancing patient-centered and safe pain care for non-surgical inpatients: clinical and managerial perspectives. Jt Comm J Qual Patient Saf. 2019;45(4):241-248. doi:10.1016/j.jcjq.2018.11.004 (impact factor 1.7; H-index 79; 1^st Quartile in Leadership & Management; impact factor and quartile are from SCIMAGO, because unavailable from Journal Citation Reports). Available at: https://pubmed.ncbi.nlm.nih.gov/30591269/
• Andraka-Christou B, Rager J, Brown-Podgorski B, M, Silverman, R, Watson, D. An integrative systematic review of the medical literature on pain clinic definitions and comparison with existing state laws and regulations. Subst Abuse Treat Prev Policy. 2018;13(1):17. Published 2018 May 22. doi:10.1186/s13011-018-0153-6 (impact factor 3.12; 3rd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/29789018/
• Andraka-Christou B, Capone M^S. Qualitative Study Comparing Physician-Reported Barriers to Buprenorphine & Extended-Release Naltrexone Prescribing in U.S. Office-Based Practices. Int J Drug Policy. 2018;54:9-17. doi:10.1016/j.drugpo.2017.11.021 (impact factor 5.3; 1st Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/29324253/
• Arnaudo C, Andraka-Christou B, Algood K. Psychiatric Co-Morbidities in Pregnant Women with Opioid Use Disorders: Prevalence, Impact, and Implications for Treatment. Curr Addict Rep. 2017;4(1):1-13. doi:10.1007/s40429-017-0132-4 (impact factor 3.2, H-index 20; 1^st Quartile in Clinical Psychology; impact factor and quartile are from SCIMAGO, because unavailable from Journal Citation Reports). Available at: https://pubmed.ncbi.nlm.nih.gov/28357191/
• Andraka-Christou B. A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction: An Editorial from a Legal Perspective. Int Rev Neurobiol. 2016;126:15-38. doi:10.1016/bs.irn.2016.02.003 (impact factor 2.5; Quartile 3 in Neurosciences). Available at: https://pubmed.ncbi.nlm.nih.gov/27055610/
• Madeira JL, Andraka-Christou B. Paper Trails, Trailing Behind: Improving Informed Consent to IVF through Multimedia Applications. J Law Biosci. 2016;3(1):2-38. Published 2016 Jan 18. doi:10.1093/jlb/lsv054 (peer-reviewed law journal; impact factor 2.2; H-index 18; 1^st Quartile in Law; impact factor and quartile are from SCIMAGO, because unavailable from Journal Citation Reports). Available at: https://pubmed.ncbi.nlm.nih.gov/27774231/
• Andraka-Christou B. America Needs the TREAT Act: Expanding Access to Effective     Medication for Treating Addiction. Health Matrix Clevel. 2016;26:309-362. PMID: 27263255 (peer-reviewed law journal; impact factor 0.24; quartile not assigned; impact factor and quartile are from SCIMAGO, because unavailable from Journal Citation Reports). Available at: https://pubmed.ncbi.nlm.nih.gov/27263255/
• Public Policy Lessons from the Orphan Drug Act: Applications for Health Policy Advocates. J Entrepreneurship Public Policy.2015; 4(3): 278-297. doi: 10.1108/JEPP-12-2013-0052 (impact factor 1.1; 2^nd Quartile in Urban Studies; impact factor and quartile are from SCIMAGO, because unavailable from Journal Citation Reports). Available at: https://www.emerald.com/insight/content/doi/10.1108/JEPP-12-2013-0052/full/html

Invited Publications

• Watson D, Andraka‐Christou B, Clark T, Wiegandt J. Introduction to the special issue on innovative interventions and approaches to expand medication assisted treatment: Seizing research opportunities made available by the opioid STR program. J Subst Abuse Treat. 2020; 108: 1-3. doi: 10.1016/j.jsat.2019.10.004. (impact factor 4.0; 2^nd Quartile in Substance Abuse).  Available at: https://pubmed.ncbi.nlm.nih.gov/31668689/

Book Chapters

• Madeira J, Andraka-Christou B, Eldridge L, Silverman R. Clouded Judgment: Preventing Conflicts of Interest in Problem-Solving Courts.” In: Cohen IG, Minssen T, Price II N, Robertson C, & Shachar C, eds. The Future of Medical Device Regulation: Innovation and Protection. Cambridge University Press. 2022. https://www.cambridge.org/core/books/future-of-medical-device-regulation/clouded-judgment/642F9C23D8D5C3CB5DEB253DE63B99A2

Other Publications

• Totaram R, Ahmed F, Andraka-Christou B, Atkins D, Asi Y. Service Modifications During COVID-19 and its Impact on Problem-Solving Courts. International Association of Forensic Mental Health Services Newsletter. 2022;7(1):7. Available at: http://iafmhs.org/resources/Documents/Newsletter/IAFMHS%20Newsletter%202022%207(1)%20Winter%20.pdf
• Andraka-Christou B, Atkins D, Asi Y. Mentoring Female & Minoritized Doctoral Students: Results and Lessons Learned. Pre-Academia Mentoring Pod, University of Central Florida: Orlando, Florida. 2021. Available at: https://ccie.ucf.edu/wp-content/uploads/sites/12/2021/11/Pre-AcademiaMentoringPod.pdf
• Andraka-Christou B, Koval A, Belanger K, Randall-Kosich O, Totaram R, Atkins D, Mazurenko O. Operationalization of Person-Centered Care: A Survey of Staff in South Florida Health Facilities. Person-Centered Care in Behavioral Health Working Group, University of Central Florida: Orlando, Florida. 2021. Available at: https://ccie.ucf.edu/wp-content/uploads/sites/12/2021/02/Final-PCC-Staff-Report.pdf
• Andraka Christou, B., Belanger, K., Koval, A., Totaram, R., Randall-Kosich, O., Atkins, D., & Mazurenko, O. Operationalization of Person-Centered Care: A Survey of Clients in South Florida Health Facilities. Person-Centered Care in Behavioral Health Working Group, University of Central Florida: Orlando, Florida. 2021. Available at: https://ccie.ucf.edu/wp-content/uploads/sites/12/2021/02/Final-PCC-Client-Report.pdf
• Andraka-Christou, B. Eight Dimensions of Person-Centered Care Critical to Improving Substance Use Disorder Treatment. Person-Centered Care in Behavioral Health Working Group, Academy Health: Washington, D.C. 2020. Available at: https://academyhealth.org/sites/default/files/researchtoimprovepccforsud_october2020.pdf
• Andraka‐Christou B, Gordon A, Bouskill K, Smart R, Randall-Kosich O, Golan M, Totaram R, Stein BD. Toward a typology of office-based buprenorphine treatment laws: themes from a review of state laws. Conference abstract published in Addict Sci Clin Pract. 2020; 15(2): A107. (impact factor 4; 2^nd Quartile in Substance Abuse). Available at: https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-020-00208-4
• Randall-Kosich O, Andraka‐Christou B, Totaram R, Cortelyou-Ward K, Atkins D, Koval A. Operationalizing person-centered care in behavioral health treatment: how can treatment centers implement respect for patient values, preferences, and expressed needs? Conference abstract published in Addict Sci Clin Pract. 2020; 15(2): A100. (impact factor 4; 2^nd Quartile in Substance Abuse). Available at: https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-020-00208-4
• Danielson EC, Mazurenko O, Andraka‐Christou B, DiIulio J, Downs SM, Hurley RW, Harle CA. How do primary care clinicians and patients discuss risks, benefits, and goals in chronic opioid therapy? Peer-reviewed abstract in J Pain. 2018; 19(3): S73‐74. (impact factor 7; 1^st Quartile in Neurosciences). Available at: https://www.jpain.org/article/S1526-5900(17)30982-3/fulltext
• Andraka-Christou, B. Individuals Suffering from Substance Use Disorder Need Treatment, Not Prisons. Ohio State University, Moritz School of Law, Drug Enforcement & Policy Center. Expert commentary. 2018. Available at: https://moritzlaw.osu.edu/depc/wp-content/uploads/sites/115/2018/10/Barbara-Andraka-Christou.pdf
• Haffajee R, Andraka-Christou B, Foney D, Beck A, Page C, Buche J. Nurse Practitioner and Physician Assistant Provision of Medication-Assisted Treatment for Opioid Use Disorder: A Survey of Knowledge, Engagement, and Perceptions. University of Michigan Behavioral Health Workforce Research Center. October 2018. Available at: http://www.behavioralhealthworkforce.org/wp-content/uploads/2019/01/Y3-FA3-P2-NP-PA-MAT-Full-Report.pdf
• Atterman J, Dormond M, Schreiber J, Haffajee R, Andraka-Christou B, Singer P, Haworth S, Foney D, Pozuelos S. Behavioral Workforce Implementation Challenges Related to Medication-Assisted Treatment. University of Michigan Behavioral Health Workforce Research Center. 2018. Available at: http://www.behavioralhealthworkforce.org/wp-content/uploads/2018/04/Y2FA3P2_MAT-Full-Report.pdf.
• Andraka-Christou, B. Improving Drug Courts through Medication-Assisted Treatment for Addiction. Va J Soc Pol Law. 2016; 23(2): 179-229. (law journal). Available at: https://heinonline.org/HOL/LandingPage?handle=hein.journals/vajsplw23&div=11&id=&page=
• Andraka-Christou, B. What is Treatment for Opiate Addiction in Problem- Solving Courts? A Study of 20 Indiana Drug and Veterans Courts. Stanford J CRCL. 2017; 13(2): 189-254. Available at: https://law.stanford.edu/publications/what-is-treatment-for-opioid-addiction-in-problem-solving-courts-a-study-of-20-indiana-drug-and-veterans-courts/
• Andraka-Christou, B. Bringing SUD Treatment into Mainstream Medicine. Guest Column. Indiana State Medical Association Reports. 2016; 12: 6. *